Ocugen Provides Business Update with First Quarter 2026 Financial Results
Ocugen announced strong 12-month Phase 2 data for its OCU410 treatment for geographic atrophy, showing statistically significant lesion reduction, completed enrollment in its Phase 3 trials for retinitis pigmentosa and Stargardt disease, and raised $115 million through convertible notes extending cash runway into 2028. The company plans multiple bi…